6:00 p.m. CET – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces its participation in the following investor events :
• ODDO BHF Forum (January 9 and 10, 2023, virtual)
As part of these professional meetings with the financial community, through “one-to-one” or “one-to-few” formats, Adocia’s management will discuss Adocia’s news and the outlook for the year 2023.
• JPM 2023 – 41st Annual Healthcare Meeting (9 – 12 January 2023, in San Francisco)
Adocia will be present at JP Morgan 2023 and will meet investors and healthcare leaders.
• Biotech Showcase (9 – 11 January 2023, in San Francisco)
Olivier Soula, Deputy CEO, will give a presentation at Biotech Showcase on January 10 on the theme: Innovation in the field of diabetes and “diabesity”, from the administration of proteins to cell therapy.
During this conference dedicated to investors, Olivier Soula will review the progress of Adocia’s flagship clinical programs in diabetes (BioChaperone® Lispro and M1Pram) and the latest results of AdoShell® technology in cell therapy.